Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...

Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than ...

The Metastatic Prostate Cancer clinical trial analysis report delivers important insights into ongoing research of 80+ ...

Learn about common side effects of radioligand therapy for metastatic prostate cancer and effective strategies to manage them for better outcomes.

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Scientists identified a driver of aggressive prostate cancer and a potential way to stop drug-resistant tumors forming.

But new, targeted forms of treatment are available, and they are transforming the landscape of prostate cancer care. One of these newer treatments is called prostate-specific membrane antigen (PSMA) ...

"The number of men living with prostate cancer also continues to rise, so it's vital that we see investment in prostate ...

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...

Chinese researchers have developed and externally validated a prediction model combining PSA, tumor stage, biopsy grade, and ...

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, today announced that the first patient has been successfully imaged in a Phase 2 clinical trial evaluating the diagnostic accuracy and ...

Prostate cancer has a well-earned reputation for being one of the more trackable malignancies in medicine. Since the mid-1980s, a single blood test measuring prostate-specific antigen, or PSA, has ...